Skip to content

Effect of chemotherapy for GG5nmHSPC: the prospective non-randomized trial

Effect of chemotherapy with standard of care for Gleason grade group 5 non-metastatic hormonal sensitive prostate cancer: the prospective non-randomized trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200062371
Enrollment
Unknown
Registered
2022-08-03
Start date
2022-08-01
Completion date
Unknown
Last updated
2023-04-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

prostate cancer

Interventions

Sponsors

Peking University First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patient who was diagnosed with prostate cancer by pathology, the Gleason Score is 9-10 (ISUP group 5); 2. Patient who had complete imaging examination and is confirmed no distant metastasis; 3. Patient who received radical local treatment recommended by NCCN guidelines (i.e. radical surgery or radical radiotherapy). 4. Patient who had expected survival time more than 12 months; 5. Aged >=18 years

Exclusion criteria

Exclusion criteria: 1. Patients who had a history of malignant tumors (except skin cancer of non-malignant melanoma and tumors that have been cured for more than 5 years); 2. Patients who had received abdominal radiotherapy; 3. Weight loss > 10% within 6 months; 4. Inability to give informed consent.

Design outcomes

Primary

MeasureTime frame
Event free survival,EFS;

Secondary

MeasureTime frame
Distance metastasis free survival,DMFS;Overall survival;

Countries

China

Contacts

Public ContactXianshu Gao

Peking University First Hospital

13911208977@139.com+86 13911208977

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026